Evidence map›Paper›PMID 34073507›Full record

ReviewCancers2021

Therapeutics Targeting the Core Apoptotic Machinery.

Claudia Hamilton, Jennifer P Fox, Daniel B Longley, Catherine A Higgins

Erratum issuedOpen access · goldAbstract readReview
In one paragraph

Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Synthesis and Anticancer Activity of New Quinazolin-4(3Pharmaceuticals (Basel, Switzerland) · 2026
    Article
  3. Article
  4. Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer.International journal of molecular sciences · 2025
    Review
  5. Article
  6. Review
  7. Cell death in cancer chemotherapy using taxanes.Frontiers in pharmacology · 2023
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Claudia HamiltonPatrick G. Johnston Centre for Cancer Research, Queens University, Belfast BT9 7BL, UK.
Jennifer P FoxPatrick G. Johnston Centre for Cancer Research, Queens University, Belfast BT9 7BL, UK.
Daniel B LongleyPatrick G. Johnston Centre for Cancer Research, Queens University, Belfast BT9 7BL, UK.
Catherine A HigginsPatrick G. Johnston Centre for Cancer Research, Queens University, Belfast BT9 7BL, UK.ORCID 0000-0002-7801-9452
Queen's University Belfast · GB

Funding

Biotechnology and Biological Sciences Research Council BB/T002824/1Cancer Research UK 24387Medical Research Council G0400302Medical Research Council MR/S021205/1Wellcome Trust 110371/Z/15/Z
6 · The paper itself

Abstract

Therapeutic targeting of the apoptotic pathways for the treatment of cancer is emerging as a valid and exciting approach in anti-cancer therapeutics. Accumulating evidence demonstrates that cancer cells are typically "addicted" to a small number of anti-apoptotic proteins for their survival, and direct targeting of these proteins could provide valuable approaches for directly killing cancer cells. Several approaches and agents are in clinical development targeting either the intrinsic mitochondrial apoptotic pathway or the extrinsic death receptor mediated pathways. In this review, we discuss the main apoptosis pathways and the key molecular targets which are the subject of several drug development approaches, the clinical development of these agents and the emerging resistance factors and combinatorial treatment approaches for this class of agents with existing and emerging novel targeted anti-cancer therapeutics.

Indexed as

apoptosiscancer therapeuticsFLIPresistance

Identifiers

PMID34073507
PMCPMC8198123
OpenAlexW3164877207

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.